Streamlining CGT Workflows: Overcoming Data Management Challenges in TCR Engineering

The biopharma R&D landscape is rapidly evolving as cell and gene therapies (CGT) move toward mainstream clinical development¹. Within this space,  T-cell receptor (TCR)-based immunotherapies are emerging as a powerful oncology modality. Unlike chimeric antigen receptor T-cell (CAR T) therapies that target cell-surface antigens, engineered TCRs can recognize intracellular peptides presented by the major histocompatibility complex (MHC), opening access to a far broader range of cancer-associated targets.

These innovations generate extensive, multimodal datasets spanning immunopeptidomics, next-generation sequencing (NGS), protein engineering, and functional screening². For organizations advancing TCR pipelines, the challenge is not only the underlying biology but also managing and interpreting this data at scale. Without a structured data-management framework, critical results can become difficult to access or trace, creating bottlenecks that slow discovery and delay downstream development. 

Immatics, a biopharmaceutical company pioneering TCR-based immunotherapies for solid tumors, faces these challenges firsthand³. Through its XPRESIDENT^® and XCEPTOR^® platforms, the company identifies tumor targets and engineers optimized TCRs for both cell-based and bispecific modalities. As its R&D activities expanded, Immatics recognized the need for a digital infrastructure that could support complex, multi-stage workflows and ensure consistent, integrated data across discovery, engineering, and analytics.

Key Challenges in Scaling TCR-Based Immunotherapy Development

The path from identifying an antigen to advancing a TCR candidate into preclinical development depends on fast, reliable access to high-quality data. As organizations scale their TCR engineering efforts, systemic data-management challenges often emerge, creating inefficiencies that slow discovery timelines.

Fragmented Data Silos in CGT R&D

In many R&D organizations, essential scientific information is scattered across disconnected systems and local file stores. Mass spectrometry results, sequencing data, protein engineering records, and in vitro assay outputs often reside in separate applications or spreadsheets, creating silos that make it difficult to assemble a complete view of each construct or experiment. This fragmentation limits integrative analysis, complicates compliance requirements for CGT programs, and forces scientists to spend valuable time manually reconciling information instead of accelerating discovery.

Data-Integration Barriers Across R&D Teams

TCR development requires close coordination across discovery biology, protein engineering, bioinformatics, and translational assay groups. Without a unified data backbone, these teams struggle to align results during critical stages such as affinity maturation and specificity optimization. Binding kinetics, epitope coverage, stability, expression, and off-target assessments must be evaluated together to guide decisions. When data remains scattered, teams risk redundant experiments, slower design–build–test–learn cycles, and decisions made with incomplete context. Highly trained scientists then spend substantial effort locating, cleaning, and reconciling data rather than generating new insights.

Legacy Systems and Traceability Gaps in Hit Selection

Many organizations still rely on paper notebooks, standalone spreadsheets, and simple file shares that cannot support the scale and complexity of modern CGT discovery. These manual or semi-manual approaches create traceability gaps that make it difficult to reconstruct the full lineage of a TCR candidate across cloning, engineering, and testing steps. During high-throughput hit selection, when thousands of variants are evaluated, missing audit trails or mislinked records can compromise data integrity and weaken downstream development packages for partners or regulatory groups.

Simplified Discovery Workflows: The Key to Accelerating CGT

To overcome growing data-management challenges, leading biopharma organizations are adopting enterprise-grade data management systems that unify and automate complex discovery workflows. This shift transforms data from an operational bottleneck into a strategic asset, enabling faster, more confident decision-making across TCR immunotherapy R&D.

Power of Structured Data-Management 

Modern R&D data infrastructures provide a centralized foundation for CGT research, supporting workflows from early antigen and TCR discovery through protein engineering, molecular characterization, and preclinical candidate nomination. By consolidating sequence data, assay results, sample metadata, and workflow status into a single, structured environment, this approach replaces fragmented, multi-tool setups. Scientific and informatics teams can then focus on interpretation and hypothesis generation rather than locating and reconciling data. 

Centralized Access and Real-Time Collaboration

A key advantage of centralized data management is the creation of a single, authoritative source of truth. Centralized storage and real-time updates ensure that all contributors  — internal teams and external partners alike — work from the same current dataset. This transparency improves coordination across disciplines and enables faster feedback loops between target discovery, TCR engineering, and functional validation, resulting in smoother handoffs and more consistent decision-making. 

Genedata Biologics as a Strong Fit for Immatics

Immatics selected Genedata Biologics, part of the Genedata Biopharma Platform, as the digital backbone for its TCR discovery and engineering workflows, complementing its XPRESIDENT^® and XCEPTOR^® technologies and broader CGT strategy. The solution’s out-of-the-box functionality is purpose-built for large-molecule and CGT R&D, enabling rapid deployment without extensive custom development. As a result, Immatics can capture, connect, and analyze TCR-related data, from tumor target identification through engineered variants and bispecific constructs, within a single platform designed for translational research.

Key Capabilities in Action

Genedata Biologics delivers capabilities that directly address the operational demands of TCR engineering:

• Molecular workspace for systematic design, registration, and tracking of TCR constructs and components
• Optimization library management to structure parental clones and affinity-matured variants, including detailed tracking of CDR changes and library composition across campaigns
• Integrated dashboards that combine sequence, expression, and functional assay data to support multi-parameter hit selection and prioritization
• Real-time data access to accelerate analysis, cross-study comparison, and collaboration

Together, these capabilities streamline hit selection and affinity maturation while delivering industrial-grade data rigor without lengthy setup cycles.

Off-the-Shelf Advantages Over Custom Builds

Immatics’ adoption of a commercial off-the-shelf solution reflects a broader shift in biopharma informatics. Compared with custom systems, such a solution offers faster implementation, configurable yet standardized functionality, and continuous evolution driven by industry needs. By leveraging the Genedata Biologics, Immatics established a scalable, future-ready informatics backbone — without diverting internal resources away from core scientific innovation.

References

1. Malviya, M.; Aretz, Z. E. H.; Molvi, Z.; Lee, J.; Pierre, S.; Wallisch, P.; Dao, T.; Scheinberg, D. A. Challenges and Solutions for Therapeutic TCR‐based Agents. Immunol. Rev.2023, 320 (1), 58–82. https://doi.org/10.1111/imr.13233.
2. Katayama, Y.; Yokota, R.; Akiyama, T.; Kobayashi, T. J. Machine Learning Approaches to TCR Repertoire Analysis. Front. Immunol.2022, 13, 858057. https://doi.org/10.3389/fimmu.2022.858057.
3. Ammar, D.; Schapitz, I.; Luu, M.; Hudecek, M.; Meyer, M.; Taps, T.; Schröder, B.; Ivics, Z.; Sanges, C.; Franz, P.; Koehl, U.; Negre, H.; Johanna, I.; Awigena-Cook, J. Accelerating Development of Engineered T Cell Therapies in the EU: Current Regulatory Framework for Studying Multiple Product Versions and T2EVOLVE Recommendations. Front. Immunol.2023, 14, 1280826. https://doi.org/10.3389/fimmu.2023.1280826.